Benefit of β-blocker treatment for patients with acute myocardial infarction and preserved systolic function after percutaneous coronary intervention

Heart

Volumn 100, Issue 6, 2014, Pages 492-499

  Choo, Eun Ho ^a   Chang, Kiyuk ^a   Ahn, Youngkeun ^b   Jeon, Doo Soo ^c   Lee, Jong Min ^d   Kim, Dong Bin ^e   Her, Sung Ho ^f   Park, Chul Soo ^g   Kim, Hee Yeol ^h   Yoo, Ki Dong ⁱ   Jeong, Myung Ho ^b   Seung, Ki Bae ^a  

^a The Catholic University of Korea   (South Korea)

^b Chonnam National University Medical School   (South Korea)

^c Bupyeong gu   (South Korea)

^d Uijeongbu St Mary's Hospital   (South Korea)

^e The Catholic University of Korea   (South Korea)

^f Daejeon St Mary's Hospital   (South Korea)

^g The Catholic University of Korea   (South Korea)

^h The Catholic University of Korea   (South Korea)

ⁱ The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL;

ACUTE HEART INFARCTION; ADULT; ANGIOCARDIOGRAPHY; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; CONTROLLED STUDY; DRUG DOSE TITRATION; FEMALE; HEART DEATH; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROPENSITY SCORE; SYSTOLE;

ADRENERGIC BETA-ANTAGONISTS; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; REGISTRIES; REPUBLIC OF KOREA; SURVIVAL RATE; SYSTOLE; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 84896731867     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2013-305137     Document Type: Article

References (26)

1. Fox KA, Steg PG, Eagle KA, et al. Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006. JAMA 2007;297:1892-900. (Pubitemid 46707843)
2. Ford ES, Ajani UA, Croft JB, et al. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med 2007;356:2388-98. (Pubitemid 46883773)
3. Anderson JL, Adams CD, Antman EM, et al. 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013;127:e663-828.
4. O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013;127:e362-425.
5. Anon. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA 1982;247:1707-14.
6. Anon. A randomized trial of propranolol in patients with acute myocardial infarction. II. Morbidity results. JAMA 1983;250:2814-19.
7. Anon. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981;304:801-7.
8. Freemantle N, Cleland J, Young P, et al. Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ (Clin Res Ed) 1999;318:1730-7. (Pubitemid 29290470)
9. Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association. J Am Coll Cardiol 2011;58:2432-46.
10. Kernis SJ, Harjai KJ, Stone GW, et al. Does beta-blocker therapy improve clinical outcomes of acute myocardial infarction after successful primary angioplasty? J Am Coll Cardiol 2004;43:1773-9. (Pubitemid 38622513)
11. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;62:1495-539.
12. Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat 2011;10:150-61.
13. Cohen J. Statistical power analysis for the behavioral sciences (rev. ed.). Hillsdale, NJ, USA: Lawrence Erlbaum Associates Inc, 1977.
14. Kezerashvili A, Marzo K, De Leon J. Beta blocker use after acute myocardial infarction in the patient with normal systolic function: when is it "ok" to discontinue? Curr Cardiol Rev 2012;8:77-84.
15. Olsson G, Rehnqvist N, Sjogren A, et al. Long-term treatment with metoprolol after myocardial infarction: effect on 3 year mortality and morbidity. J Am Coll Cardiol 1985;5:1428-37. (Pubitemid 15069520)
16. Nakatani D, Sakata Y, Suna S, et al. Impact of beta blockade therapy on long-term mortality after ST-segment elevation acute myocardial infarction in the percutaneous coronary intervention era. Am J Cardiol 2013;111:457-64.
17. Ozasa N, Kimura T, Morimoto T, et al. Lack of effect of oral beta-blocker therapy at discharge on long-term clinical outcomes of ST-segment elevation acute myocardial infarction after primary percutaneous coronary intervention. Am J Cardiol 2010;106:1225-33.
18. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001;357:1385-90. (Pubitemid 32455364)
19. Chan MY, Sun JL, Newby LK, et al. Long-term mortality of patients undergoing cardiac catheterization for ST-elevation and non-ST-elevation myocardial infarction. Circulation 2009;119:3110-17.
20. Ellis K, Tcheng JE, Sapp S, et al. Mortality benefit of beta blockade in patients with acute coronary syndromes undergoing coronary intervention: pooled results from the Epic, Epilog, Epistent, Capture and Rapport Trials. J Interv Cardiol 2003;16: 299-305. (Pubitemid 37047125)
21. Duncker DJ, Boontje NM, Merkus D, et al. Prevention of myofilament dysfunction by beta-blocker therapy in postinfarct remodeling. Circ Heart Fail 2009;2: 233-42.
22. Doughty RN, Whalley GA, Walsh HA, et al. Effects of carvedilol on left ventricular remodeling after acute myocardial infarction: the CAPRICORN Echo Substudy. Circulation 2004;109:201-6. (Pubitemid 38114140)
23. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 1990;81:1161-72. (Pubitemid 20119612)
24. Patel MR, Westerhout CM, Granger CB, et al. Aborted myocardial infarction after primary percutaneous coronary intervention: magnetic resonance imaging insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial. Am Heart J 2013;165:226-33.
25. Chan J, Khafagi F, Young AA, et al. Impact of coronary revascularization and transmural extent of scar on regional left ventricular remodelling. Eur Heart J 2008;29:1608-17. (Pubitemid 351957551)
26. Dutta P, Courties G, Wei Y, et al. Myocardial infarction accelerates atherosclerosis. Nature 2012;487:325-9.